Skip to main content
S 3792 115th Congress Senate Health Administrative law and regulatory procedures Civil actions and liability Competition and antitrust Contracts and agency Federal Trade Commission (FTC) Intellectual property Judicial review and appeals Licensing and registrations Marketing and advertising Prescription drugs

Preserve Access to Affordable Generics and Biosimilars Act

Introduced: December 19, 2018 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 19, 2018
Read twice and referred to the Committee on the Judiciary.
Dec 19, 2018
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Preserve Access to Affordable Generics and Biosimilars Act

This bill amends the Federal Trade Commission Act to authorize the Federal Trade Commission to initiate proceedings against parties to any agreement resolving or settling a patent infringement claim in connection with the sale of a drug or biological product. Such an agreement, with specified exceptions, is presumed to have anticompetitive effects and violates this bill if the filer of an abbreviated new drug (generic) application or a biosimilar biological product application: (1) receives anything of value; and (2) agrees to limit or forego research, development, manufacturing, marketing, or sales of the generic drug or biosimilar biological product for any period of time.

What's happening now December 19, 2018

Read twice and referred to the Committee on the Judiciary.

 Related & companion bills 1
  • S 124 Related bill Preserve Access to Affordable Generics Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Republican 1
R
Grassley, Chuck
Iowa · Dec 19, 2018
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3792: Preserve Access to Affordable Generics and Biosimilars Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-3792/
MLA
"S. 3792: Preserve Access to Affordable Generics and Biosimilars Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-3792/.
Bluebook (legal)
S. 3792, 115th Cong. (2026), https://openamerica.io/bill/115-S-3792/.
Markdown link
[S. 3792: Preserve Access to Affordable Generics and Biosimilars Act](https://openamerica.io/bill/115-S-3792/)
Report a problem